Thinking January 27, 2026

The impact of GLP-1 demand on the autoinjector supply chain

Josh Lowth
By
Josh Lowth Category Marketing Manager - Pharmaceuticals and Drug Delivery

The global pharmaceutical landscape is undergoing a seismic shift driven by the explosive growth of GLP-1 therapies. Originally developed for diabetes management, these treatments have expanded into weight management and other indications, creating unprecedented demand for drug-device combination products.

Autoinjectors, once a niche solution, are now at the centre of this transformation. At Ensera, we’re seeing how this surge has placed immense pressure on supply chains, manufacturing capacity, and strategic planning across the industry. Josh Lowth, John Ward and Marcel Baumann take a look at the impact as seen from Ensera’s perspective and explore how the market can adapt.

The GLP-1 surge and its ripple effect

GLP-1 therapies have not only reshaped treatment paradigms but also revolutionized device strategies. Historically, pharmaceutical companies would invest in bespoke autoinjector designs. A costly and time-intensive approach. Today, the urgency to bring products to market has accelerated the development and adoption of platform-based autoinjectors. Off-the-shelf solutions from established players such as our partners, SHL, Ypsomed and BD dominate the market, offering proven reliability, scalability, cost efficiencies and speed.

We’ve seen how this shift has also influenced broader trends in self-administration. Prefilled syringes, while less directly tied to GLP-1 growth, continue to gain traction as healthcare systems prioritize home-based care. By reducing reliance on vial-based administration, these devices minimize human error and streamline treatment processes – critical factors in an era of rising healthcare costs.

Supply chain bottlenecks: where the strain is most acute 

The scale-up of GLP-1 therapies has exposed vulnerabilities across the autoinjector supply chain for all therapies that require this delivery format. Equipment lead times for final assembly services can stretch to 18–24 months, creating significant delays in capacity expansion. Fill-finish operations remain a bottleneck, with lead times often exceeding one year during peak demand periods. 

Device assembly and secondary packaging are similarly affected. Large providers often prioritize high-volume projects, leaving smaller runs, such as clinical trials, rare disease treatments, and orphan drugs, struggling to secure capacity. This imbalance underscores the need for agile partners like Ensera, who can support niche programs without compromising timelines or quality. 

“Final assembly and secondary packing have definitely been pinch points. This is due to the long equipment lead times. But then you add qualification, validation, and people training. That’s how a year turns into two or three. So even after new lines arrive, the market can still feel tight.”

- John Ward, VP Pharma EMEA, Ensera

Regional dynamics: Europe vs North America

North America, characterized by large-scale operations and simpler labeling requirements, has felt the pressure earlier and more intensely. The US market typically involves fewer SKUs, amplifying the effect of capacity constraints as manufacturers focus on high-volume production. 

Europe has a more fragmented landscape, with diverse regulatory and labeling requirements necessitating smaller batch runs. This complexity mitigates some supply chain stress but introduces its own challenges in managing variability and ensuring compliance.  

We’ve noticed, that across both regions, smaller programs are increasingly deprioritized. This is a trend that demands innovative solutions and flexible manufacturing models. 

“Across both regions, we see the same effect again and again: Blockbuster products absorb all the capacity. Small and mid‑sized projects struggle to get time on lines.” 

- Marcel Baumann, VP Sales Pharma USA, Ensera

Strategic shifts in pharma device planning

Pharmaceutical companies are responding to these pressures with strategic adaptations. Guaranteed capacity agreements and long-term supply commitments are becoming standard practice, providing assurance against future bottlenecks. The move towards platform-based devices reflects a pragmatic approach to risk mitigation, enabling rapid deployment while reducing regulatory hurdles. 

Customization is also becoming a valuable differentiator, allowing brands to tailor aesthetics and functionality within established platforms. This hybrid strategy combines speed to market with brand identity, offering the best of both worlds. We support this approach at Ensera through specialist design expertise and modular manufacturing capabilities, helping clients achieve differentiation without compromising on timelines. 

Two people using XpressCollect(TM) sample collection device.

“The other shift is we’ve seen is around mindsets. Pharma companies want guaranteed capacity and volume and so are looking to tie suppliers in for the long-term. And it’s sensible, because if capacity isn’t secured, speed‑to‑market can stall quickly.”

- John Ward, VP Pharma EMEA, Ensera

The critical role of early collaboration

Early engagement between pharma companies, device manufacturers, and supply chain partners is essential for success. Delayed involvement often results in suboptimal solutions, increased costs, and heightened regulatory risk. Whereas integrated planning enables comprehensive testing, validation, and customization, ensuring alignment across the product lifecycle.

Packaging, often considered late in the process, requires equal attention. Validated, repeatable, and risk-managed methodologies are critical for maintaining product integrity and patient safety.

Quality and regulatory expectations at scale

Despite rising volumes, compliance expectations remain unchanged. Leading manufacturers have scaled responsibly, investing in automation and advanced technologies to maintain stringent standards. At Ensera, we too operate within this framework combining rigorous quality controls with flexible capacity to meet diverse client needs. Our commitment to excellence ensures that every project, regardless of scale, meets the high standards of safety and reliability expected.

“The rules haven’t changed. Quality is non‑negotiable. Regulatory steps take the time they take. What’s different now is the volume of demand. It magnifies any weak link.”

- John Ward, VP Pharma EMEA, Ensera

Flexibility and modularity: building resilient supply chains

Unlike providers constrained by GLP-1 high-volume pressures, Ensera remains focused on small-to-mid-volume projects, clinical trials, and rare disease drugs. Our independence from the GLP-1 bottleneck allows us to offer immediate capacity, tailored solutions, and responsive service. Advantages that set us apart in a crowded market. 

Our global manufacturing footprint also gives partners greater choice in where and how their programs are executed. Which could include dual-site delivery. This adds further redundancy and risk mitigation, helping teams to navigate regional regulatory differences, unexpected capacity constraints, or logistical challenges. 

“Large, highly automated plants are brilliant for mega‑runs. But they struggle with small ones. As portfolios fragment, we need lines that can adapt, cells that re‑configure fast and tooling that swaps cleanly.”

- Marcel Baumann, VP Sales Pharma USA, Ensera

Conclusion: preparing for the future of drug delivery

The GLP-1 revolution has redefined the autoinjector supply chain, creating both challenges and opportunities. Sustained growth and success in this dynamic environment require agility, collaboration, and strategic investment. Ensera stands ready to support pharmaceutical companies with modular solutions, validated processes, and a commitment to quality and compliance, ensuring that every project, from clinical trials to commercial launches, achieves its goals.

Are you looking for a flexible partner with capacity available now?

Contact Ensera today to explore how we can help you get your next combination product to market quickly and efficiently.

View more:

All Thinking
Contact us

Discover Ensera for yourself

We’re ready and waiting to solve your design or manufacturing challenges.

Submit enquiry